HAMILTON, Bermuda, Jan. 27, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will be presenting at two upcoming investor conferences:
- February 10 at 2:15 p.m. ET at the Leerink Partners Global Healthcare Conference
- February 24 at 2:35 p.m. ET at the RBC Capital Markets 2016 Global Healthcare Conference
Axovant’s management team will present an overview of its dementia drug development pipeline which includes the Company’s global, multi-center, double-blind, placebo-controlled confirmatory Phase 3 study of RVT-101 for the treatment of mild-to-moderate Alzheimer’s disease called the MINDSET Study and additional details of the three clinical programs expected to be initiated in first quarter 2016 to address cognitive, behavioral and functional aspects of Lewy body dementia, a disease affecting approximately 1.4 million people in the U.S.
For more information about the MINDSET study please visit www.alzheimersglobalstudy.com, email mindset@axovant.com or call 646-495-8197.
A simultaneous webcast can be accessed by visiting the Investors section of www.axovant.com and selecting Events and Presentations. Replays will be available for 30 days following each conference.
About Axovant
Axovant Sciences Ltd. is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral components of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of the disease.
Logo - http://photos.prnewswire.com/prnh/20150629/226455LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/axovant-sciences-to-present-at-upcoming-investor-conferences-300210510.html
SOURCE Axovant Sciences Ltd.
